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We evaluated cardiac autonomic modulation by heart rate (HRV), and arterial pressure variability (APV), and metabolic response
in streptozotocin diabetic rats treated with green tea. Male Wistar rats were separated in groups: control, drinking tap water (C),
green tea-treated (GT) group, diabetic, drinking tap water (D), and diabetic, treated with green tea (DGT). Kidney mass was
greater in D and DGT than in C and GT, but reduced in DGT compared to D. Green tea prevented the increase in creatinine
clearance and reduced hyperglycemia in DGT compared to D. Arterial pressure was increased in GT and decreased in D compared
to C. HRV was reduced in D compared with all groups. APV was decreased in D compared to C and recovery in DGT. Sympathetic
modulation of APV was decreased in D compared with all groups. Green tea reduced hyperglycemia, prevented renal injury and
autonomic dysfunction, suggesting reduced cardiovascular risk and target organ damage in diabetes.
1.Introduction
Diabetes mellitus (DM) is a metabolic disorder character-
ized by an impairment of carbohydrate, fat, and protein
metabolism caused by either lack of insulin secretion or
decreased sensitivity of the tissues to insulin [1]. This
disease has reached epidemic levels in the United States and
threatens a worldwide epidemic. The prevalence of diabetes
is increasing rapidly, and the disease incidence in 2010 was
about 285 million people worldwide, and is projected to
increase to 438 million in 2030 [2].
A number of studies have been published concerning the
associationbetweenchronichyperglycemiaandcardiovascu-
lar complications in DM, including systemic hypertension,
atherosclerosis, nephropathy, coronary ischemia, vascular
disease, and stroke [3–7]. Dysfunction of autonomic neural
control is a frequent complication of diabetes which is
associated with high morbidity and mortality [8], and has
been found in clinical and animal models of DM [9, 10].
Methods to detect early abnormalities in cardiac autonomic
modulation in DM have been applied such as heart rate and
arterial pressure variability analysis.
Heart rate and blood pressure variability (HRV and
BPV), estimated in time or frequency (spectral analysis)
domain, have been widely used to evaluate the cardiac auto-
nomic modulation in both clinical and experimental studies
[11–16]. Heart rate as well as blood pressure oscillations at
low frequency (LF: 0.2 to 0.75Hz) is an index of cardiac
sympathetic modulation, while high-frequency (HF: 0.75 to
3Hz) oscillations of HR reﬂect parasympathetic modulation
of the heart [17]. The importance of HRV and BPV was
established with reports that showed a reduction in HRV
and/or increased in BPV is associated with a large number of
pathologies like diabetes and cardiovascular diseases [12, 16,
18, 19]. Moreover, there is evidence showing that decrease in
HRV is an independent predictor of sudden cardiac death as
wellasincreasedBPVwasassociatedwithend-organdamage
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Green tea (leaves of Camellia sinensis, Theaceae) is a
popular beverage in east Asia, and in recent years green tea
has been widely studied to assess its beneﬁcial eﬀects in the
treatment and prevention of human disease [23, 24]. Several
epidemiological studies and clinical trials suggest that green
tea consumption reduces the risk of many chronic diseases,
including cardiovascular diseases [23, 24]. Moreover, green
tea consumption improved glucose metabolism implicated
in DM [25, 26], revealing that green tea consumption
could be beneﬁcial in the management of DM. Additional
published studies showed that the administration of green
tea to STZ diabetic rats promoted blood glucose reduction,
hypolipidemic response, antioxidant eﬀect, improved kidney
function, and cardiac protection [27–29]. However, only
partial protection of green tea against STZ-induced hyper-
glycemia and oxidative stress has also been reported [30],
suggesting that these contradictory results could be due to
variations in severity, duration, and treatment of the disease.
Although the literature provides evidence that green tea
is useful to DM treatment, no studies to date have tested
the potential of green tea to prevent autonomic dysfunction
associated with DM. Speciﬁcally, the present study evaluates
the autonomic modulation of cardiovascular function as
measured by heart rate, arterial pressure variability, and the
metabolic response in STZ diabetic rats subject to green tea
consumption since diabetes induction.
2.MaterialsandMethods
2.1. Animals. Experiments were performed on adult male
(eight-week-old) Wistar rats weighing 260–300g. The ani-
mals were randomly separated in four experimental groups:
control, drinking tap water (C, n = 8), green tea-treated
group (GT, n = 8), diabetic, drinking tap water (D, n = 9),
and diabetic, treated with green tea (DGT, n = 10). The ani-
mals were housed in cages with free access to water and food,
at a constant temperature of 23◦C, on a 12-hour light/dark
cycle. All experimental protocols were in accordance with
the Guidelines for Ethical Care of Experimental Animals and
were approved by the Institutional Animal Care and Use
Committee (Protocol: 025/09/2008).
After the experimental period, rats were killed by over
dose of sodium pentobarbital anesthesia (50mg/Kg i.p.)
and blood glucose, and creatinine concentrations were
determinedinnonfastinganimalsusingcolorimetricenzyme
kits (LABTEST, Brazil). The kidneys were quickly removed
and the ratios of kidney: body weight (kidney mass index)
were determined.
2.2. Diabetes Induction. Diabetes was induced by a single
injection of STZ (50mg/kg, i.v., Sigma Chemical Co, St
Louis, MO, USA) dissolved in 0.05M citrate buﬀer, pH 4.5,
administered 21 days before the treatment. Controls (C and
GT) were injected with the vehicle (0.05M citrate buﬀer,
pH 4.5) alone. Animals were fasted for 4h before STZ or
vehicle injection. During the 24-hr after STZ induction (D
and DGT) or vehicle injection (C and GT), the animals were
fed with glucose solution (12.5g/L) to avoid ketoacidosis.
Two days following STZ injection, diabetes induction
was conﬁrmed by blood glucose level (10µL of blood from
tail vein) (Accu-Check Advantage Glucose Monitor, Roche
Diagnostic Corporation, Indianapolis, IN, USA). Animals
w i t hb l o o dg l u c o s el e v e l sl e s st h a n2 5 0 m g / d Lo rg r e a t e r
than 400mg/dL were excluded from the study to avoid great
discrepancies in our data due to changes in glucose levels
since it is well known the inﬂuence of glucose levels on
metabolic and cardiovascular functions.
2.3. Green Tea Preparation, Analysis, and Treatment. Green
tea was prepared daily by adding 3.0g of dry green
tea (Farmanatural, Natural Pharma, S˜ ao Paulo, Brazil) to
1000mL of boiled water cooled to 90◦C. The solution
was ﬁltered after 15min, cooled to room temperature, and
dispensed into clean drinking bottles. The total content
of caﬀeine and polyphenols in the green tea solution was
0.07% and 422.80µg/mL, respectively. Green tea solution
was administered for 21 days to the GT and DGT groups.
2.4.MetabolicCages. Inasubgroupofratsrandomlyselected
(C, n = 7; GT, n = 6; D, n = 6; DGT, n = 8), at the end of
thesecondweek(day14),animalswerehousedseparatelyfor
48h in metabolic cages (Andrade’s, S˜ ao Paulo, Brazil) with
freeaccesstofoodandtapwaterorgreenteasolution.Hydric
consumption, urinary excretion, and food intake during the
last 24h between 9:00 am and 10:00 am. Urine glucose and
creatinine were measured using a colorimetric enzyme assay
(LABTEST, Brazil).
2.5. Glucose Tolerance Test (GTT). At the end of the study, in
a subgroup of randomly selected rats (C, n = 7; GT, n = 5;
D, n = 7; DGT, n = 5), glucose was measured using an Accu-
Check Advantage Blood Glucose Monitor (Roche Diagnostic
Corporation, Indianapolis, IN, USA). Animals were fasted
for 4h, given an intraperitoneal glucose load (1.5g/kg, i.p.),
and blood samples were taken at baseline and 15, 30, 60, and
90min from a cut made on the tip of the tail.
2.6. Cardiovascular Measurements. O n ed a yp r i o rt oa r t e r i a l
pressure (AP) recordings, an arterial catheter was placed in
the right femoral artery of study animals under ketamine-
xylazine anesthesia (50:10mg/kg i.p.), for the direct mea-
surement of AP in all groups (C, n = 8; GT, n = 8; D, n = 9;
DGT, n = 10). The catheter was exteriorized through the
back of the neck.
During the study, AP was recorded during 30 minutes
via a transducer (Hewlett-Packard 1280, USA) connected
to the arterial catheter. Animals were conscious and moved
freely during recording. The AP signal was fed into an
ampliﬁer (GPA-4 model 2, Stemtech Inc.) connected to
a 16-channel analog-to-digital interface, and continuously
sampled (2kHz) on an IBM/PC (T23, IBM Thinkpad, Inc).
Beat-to-beat values of systolic, diastolic, and mean AP (SAP,
DAP and MAP, resp.) were determined, and heart rate
(HR) or pulse interval (PI) were calculated as the interval
betweensuccessivesystolicpressurevaluesusingthesoftware
application WinDaq (DataQ Instruments, Inc., USA).Experimental Diabetes Research 3
Table 1: Body weight, kidney mass index, and parameters obtained of metabolic cage.
CG TD D G T
Initial body weight (g) 280 ±6 270 ±9 265 ±4 260 ±8
Final body weight (g) 335 ±14.0 320 ±11 245 ±14
∗ 235 ±18
∗
Left kidney mass index (mg/g) 3.7 ±0.24 ±0.26 .3 ±0.2∗ 5.0 ±0.2∗#
Right kidney mass index (mg/g) 3.6 ±0.14 .3 ±0.26 .5 ±0.2∗ 5.2 ±0.2∗#
Food intake (g) 15 ±1.61 1 ±2.52 3 ±6.6
∗ 31 ±4
∗
Hydric consumption (mL/24h) 19 ±1.72 1 ±2.67 3 ±4.6
∗ 90 ±15
∗
Urinary excretion (mL/24h) 6 ±0.68 ±0.76 1 ±12
∗ 77 ±12
∗
C: control, drinking tap water group; GT: green tea-treated group; D: diabetic, drinking tap water; DGT: diabetic, treated with green tea group. Initial and
ﬁnal body weight (g) and kidney mass index (mg/g): C (n = 8), GT (n = 8), D (n = 9), and DGT (n = 10). Metabolic cage: C (n = 7), GT (n = 6), D (n = 6)
and DGT (n = 8). ∗P<0.05 versus C and GT; #P<0.05 versus D.
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Figure 1: Serum glucose concentration (a) and area under curve (AUC) of blood glucose (b) during glucose tolerance test. C: control,
drinking tap water group; GT: green tea-treated group; D: diabetic, drinking tap water; DGT: diabetic, treated with green tea group. Serum
glucose: C (n = 8), GT (n = 8), D (n = 9), and DGT (n = 10). Glucose tolerance test: C (n = 7), GT (n = 5), D (n = 7), and DGT (n = 5).
GTT: C (n = 7), GT (n = 5), D (n = 7) and DGT (n = 5). ∗P<0.05 versus C and GT; #P<0.05 versus D.
PI and SAP ﬂuctuations were assessed in the time and
frequency domains using autoregressive spectral analysis,
as described elsewhere [12, 15, 31, 32]. The theoretical
and analytical procedures for autoregressive modeling of
oscillatory components have been fully described previously
[12, 13, 17]. Brieﬂy, the PI and SAP series derived from each
recording were divided into 300-beat segments with a 50%
overlap. The spectra of each segment were calculated via
the Levinson-Durbin recursion, and the order of the model
chosen according to Akaike’s criterion, with the oscillatory
components quantiﬁed in low-(LF: 0.2 to 0.6Hz) and high-
frequency (HF: 0.6 to 3.0Hz) ranges.
2.7. Statistical Analyses. Data are reported as mean ± SEM.
Statistical analyses were performed using two-way analysis
of variance (ANOVA) followed by the Bonferroni test.
Diﬀerences were considered to be signiﬁcant at P<0.05.
3. Results
3.1. The Eﬀect of Green Tea on Metabolic Measurements.
Table 1 shows the eﬀect of diabetes and green tea consump-
tiononbodyweightandkidneymassindex.Nodiﬀerencesin
body weight were observed among groups in the beginning
of the experiment. However, both diabetic groups (D and
DGT animals) showed lower body weight compared to
nondiabetic control groups (C and GT animals) after the
period of 21 days (P<0.05). There was no signiﬁcant
diﬀerence between the mean body weights of the D group
compared with DGT showing that green tea consumption
did not prevent weight loss in diabetic animals. In fact,
while the groups C and GT showed a signiﬁcant increase in
body weight (20% and 19%, resp., P<0.05), a signiﬁcant
reduction in body weight was observed in D (7.5%) and
DGT (9.6%) groups at the end of the study. The kidney mass
index was greater in D and DGT than in C and GT animals
(P<0.05). However, green tea intake reduced the kidney
mass index in DGT animals compared with D (5.0 ± 0.2
versus 6.3 ± 0.2mg/g,resp.,P<0.05).
The induction of diabetes mellitus in the experimen-
tal animals was conﬁrmed by blood glucose value above
250mg/dL 48h after STZ induction. D and DGT ani-
mals developed hyperglycemia (577 ± 62mg/dL and 384 ±
52mg/dL, resp.), their serum glucose concentrations being
signiﬁcantly higher than nondiabetic animals (C, 232 ±
16mg/dLandGT,202±16mg/dL).Diabeticratstreatedwith
green tea (DGT) showed lower hyperglycemia than diabetic
rats not treated with green tea (D), suggesting that green tea
consumption protects from severe hyperglycemia in diabetic
rats. It is important to note that green tea did not change
the serum glucose level in GT animals (Figure 1(a)). Despite4 Experimental Diabetes Research
Table 2: Changes in urine, serum glucose, and creatinine clearance after 21 days of treatment with green tea in diabetic rats induced by
streptozotocin.
Groups C GT D DGT
Urine glicose (mg/dL) 3 ±1.71 4 ± 3.2 845 ±94
∗ 637 ±58
∗#
Serum glicose (mg/dL) 232 ±16 202 ±16 577 ±62
∗ 384 ±52
∗#
Creatinine clearance (mL/min/Kg) 0.21 ±0.03 0.43 ±0.09 1.1 ± 0.3
∗ 0.75 ±0.1
∗#
C:control,drinkingtapwater group;GT:green tea-treatedgroup;D:diabetic,drinkingtapwater; DGT:diabetic,treatedwithgreen teagroup.Serumgl u c o s e :
C( n =8), GT (n=8), D (n = 9), and DGT (n = 10). Urine glucose: C (n = 7), GT (n = 6), D (n = 6), and DGT (n = 8). ∗P<0.05 versus C and GT; #P<0.05
versus D.
Table 3: Mean arterial pressure, heart rate, and respective variabilities in time and frequency domains in diabetic rats subject to green tea
treatment.
C( n = 8) GT (n = 8) D (n = 9) DGT (n = 10)
MAP(mmHg) 106 ± 2 128 ± 3# 99 ± 1.5∗ 111 ± 4
HR (bpm) 360 ± 7 341 ± 8 295 ± 11∗ 328 ± 14
HRV (ms2)1 8 ± 1.3 16 ± 1.1 8.8 ± 0.7∗ 15 ± 1.6
APV (mmHg2)2 3 ± 3.2 31 ± 7.5 7.5 ± 0.2∗ 15 ± 4.4
LF (mmHg2)2 . 5 ± 0.36 3.8 ± 0.6 0.9 ± 0.4∗ 3.1 ± 0.8
C: control, drinking tap water group; GT: green tea-treated group; D: diabetic, drinking tap water; DGT: diabetic, treated with green tea group. MAP: mean
arterial pressure; HR: heart rate; HRV: heart rate variability; APV: arterial pressure variability; LF: low-frequency domain of APV. ∗P<0.05 versus all groups;
#P<0.05 versus C.
hyperglycemia suppression by green tea, we observed no
diﬀerences in the area under curve (AUC) of the glucose
tolerance tests between D (446 ± 29mg/dL/min) and DGT
(454 ±39mg/dL/min), nor between C (109 ±9mg/dL/min)
and GT (101±18mg/dL/min) groups, conﬁrming that green
teadidnotchangeglucosetoleranceinSTZ-induceddiabetic
rats (Figure 1(b)).
As shown in Table 1, diabetic animals (D and DGT)
showed signs of polydipsia, polyphagia, and polyuria. No
signiﬁcant diﬀerences between diabetic groups (D versus
DGT) nor between control animals (C versus GT) were
observed. The administration of green tea did not exert a
signiﬁcant eﬀect on water or food intake as well as in urine
v o l u m ec o l l e c t e di nm e t a b o l i cc a g e so v e r2 4h o u r s .H o w e v e r ,
it is important to note that DGT animals ingested higher
amount of green tea (0.3 ± 0.05g/day) than GT animals
(0.06 ± 0.01g/day). Glomerular ﬁltration rate assessed by
creatinine clearance (Table 2) was increased in diabetic
(D and DGT) compared with nondiabetic rats C and
GT (P<0.0001). Green tea consumption prevented the
strong increase in creatinine clearance in the DGT group
(0.75 ± 0.1mL/min/Kg) compared with D group (1.1 ±
0.3mL/min/Kg). However, in nondiabetic rats there was
no statistically signiﬁcant eﬀect of green tea on creatinine
clearance (0.21 ± 0.03 versus 0.43 ± 0.09mL/min/Kg, C and
GT resp.). Finally, diabetic rats treated with green tea showed
a signiﬁcant reduction in urine glucose compared with D.
Although, there was a diﬀerence between C and GT in urine
glucose, it was not statistically signiﬁcant (Table 2).
3.2. The Eﬀect of Green Tea on Cardiovascular Measurements.
The values obtained for MAP and HR are presented in
Table 3. Diabetes induced by STZ promoted attenuation in
MAP (∼10% of reduction) as well as in HR (∼20% of reduc-
tion)inDgroup.Greenteaintakepreventedthereductionof
bothparameters,MAPandHRindiabeticanimals.However,
in nondiabetic animals green tea increased MAP (∼20% of
increase) with no alterations in HR. The total power of the
HRV was reduced in D in comparison with all groups. The
APV decrease in D compared to C and recovery in DTG.
Sympathetic modulation of the arterial pressure variability
(LF) decreased in D compared with groups C, GT, and DGT.
4. Discussion
The present study was conducted to evaluate the role of
green tea consumption in metabolic response and cardiovas-
cular autonomic modulation in STZ-induced diabetic rats.
Experimental diabetes induced by STZ is a well-established
method used to evaluate the mechanisms involved in the
alterations of physiopathology observed in diabetic patients.
STZ destroys pancreatic b cells, resulting in a diabetic
syndrome in animals, similar to that seen in human type 1
diabetes and characterized by hyperglycemia, hypoinsuline-
mia, glucosuria, and loss in body weight [33–35].
Although the nondiabetic rats registered approximately
20% growth in body weight, diabetic rats showed reduced
body weight and green tea extract treatments did not im-
prove weight gain in STZ-treated animals. These responses
were also observed by Renno et al. [29]a n dJ u ´ skiewicz
et al. [30]. In other studies, the consumption of green tea
prevented the loss in body weight in STZ-treated rats [27,
28]. However, the contradictory results could be due to the
diﬀerences in dosage and methods used in dietary treatment.
Despite green tea plays an important role in the regulation of
body weight [36], our results showed that the body weight of
nondiabetic rats, C and GT, was similar. This response may
be associated with the lower content of caﬀeine in the greenExperimental Diabetes Research 5
teaextract(0.07%)usedinthepresentstudy,ifweconsidered
thatthecaﬀeineisthemainfactorinvolvedinthermogenesis,
fat oxidation, and sparing fat-free mass [37].
In the present study, diabetic-treated (DGT) and un-
treated (D) animals showed serum, and urine glucose levels
elevated compared with C group. However, we observed a
signiﬁcant reduction in both serum and urine glucose levels
in the DGT group as compared to the D group. Considering
thathyperglycemiaistheprincipalfactorresponsibleforkid-
ney and cardiovascular damage [7], the antihyperglycemic
eﬀect of green tea observed in the DGT group suggests
an important clinical relevance to diabetes treatment. In
supportofthepresentresults,recentreportshaveshownthat
green tea administration caused similar antihyperglycemic
eﬀect in STZ induced rats [28, 29], in diabetic db/db mice
[25] and in diabetes type 2 patients [38]. On the other
hand, the eﬀect of green tea on glucose tolerance was not
observed in both nondiabetic (GT) and diabetic (DGT)
groups. Similar results with glucose tolerance were shown by
Wu et al. [39].
With regard to metabolic parameters, STZ rats showed
polydipsia, polyphagia, and polyuria [27]. However, the
administration of green tea in this study did not exert a
signiﬁcant eﬀect on liquid intake or food intake as well
as in urine volume since no signiﬁcant diﬀerences among
groupswereobserved.Despiteourresultsweresimilartothat
showed by Tomlinson et al. [34], Babu et al. [27]o b s e r v e d
decreased food and water intake in diabetic rats treated with
green tea. The diﬀerences may be associated with the period
and moment that green tea treatment was introduced in STZ
rats. In the present study, green tea was administrated for 21
days following the ﬁrst day of diabetes identiﬁcation while in
the other study green tea was administrated for 4 weeks and
the treatment was begun 6 weeks after the onset of diabetes
[27].
Glomerular ﬁltration rate assessed by creatinine clear-
ance was measured in our study to provide information
about renal function. Diabetic rats (D and DGT) increased
creatinine clearance compared with nondiabetic rats C and
GT. It is interesting that green tea consumption resulted in
lower creatinine clearance in DGT compared with D, but
did not aﬀect nondiabetic rats (C versus GT), thus, our data
suggests that green tea prevents glomerular hyperﬁltration
in diabetes. In support with our data, it has been reported
that in rats with streptozotocin-induced diabetes, green tea
consumption showed a signiﬁcant reduction in renal injury
associated with hyperglycemia [29].
Diabetes caused an abnormal increase in kidney mass
index in both diabetic groups D and DGT. Interestingly,
green tea consumption by DGT group signiﬁcantly reduced
diabetes-induced hypertrophy of kidney by 20% as com-
pared to the D group. These results suggest the importance
of green tea in reducing kidney hypertrophy and corroborate
another study with STZ rats [30]. Creatinine clearance as
well as kidney mass are important markers of nephropathy
and our data are in agreement with Ribaldo et al. [40] that
showed a decrease in the markers of nephropathy in diabetic
hypertensive rats following the consumption of green tea.
In the present study, we observed in rats with STZ-
induced diabetes a reduction in AP and HR associated with
a decrease in HRV and APV as previously described [10, 41,
42]. On the other hand, there are reports of increased blood
pressure [43–45] or no change in STZ-induced diabetic rats
[46]. Some of discrepancies in the literature regarding BP
changes in STZ rats may be due to diﬀerences in age and
time of experimentation as well as the methodology for
BP measurement. However, the new data is that green tea
consumption was able to prevent all of these cardiovascular
alterations. Since the HRV and APV are useful tools to
evaluate autonomic modulation of the cardiovascular system
in humans and experimental models, our data suggests that
green tea consumption was able to reduce the autonomic
neuropathy observed in diabetes. It is well accepted that
diabetes is associated with elevated oxidative stress [47, 48],
which is correlated with alterations in the autonomic control
of the circulation [14, 49].
The favorable eﬀects attributed to the green tea extract
in the prevention of cardiovascular diseases are correlated
with the antioxidant properties of the catequins, which
are the major components of green tea [50]. Experimental
studies have been demonstrated the increase in total plasma
antioxidant activity determined by green tea catequins [51,
52]. Moreover, in vitro studies have demonstrated that green
tea extracts and tannin mixtures have a direct scavenging
activity against nitric oxide and superoxides [53]. Thus, we
canhypothesizethatantioxidants,suchasgreenteamayhave
beneﬁcial eﬀects on the cardiovascular autonomic nervous
system. In fact, previous studies showed that the administra-
tion of antioxidants, like vitamin E, exerts beneﬁcial eﬀects
on the cardiac control by rebalancing autonomic nervous
system in diabetes [54]. Therefore, when taken together,
these data support the conclusion that other studies need to
be carried out to better understand the mechanisms involved
in green tea pharmacological action and also reveal that
indiscriminate chronic consumption of green tea might be
a risk for health individuals, since in our study we have
observed that the green tea ingestion determined an increase
in blood pressure in GT.
In summary, the major ﬁndings of this study are that
green tea decreased hyperglycemia and prevented renal
injury by improvement of glomerular ﬁltration and kidney
hypertrophy observed in diabetic rats. Moreover, green tea
was able to prevent the autonomic dysfunction in diabetic
ratsbyblockingthealterationsinarterialpressurevariability.
In conclusion, our data suggest that green tea consumption
has important eﬀects in reducing the cardiovascular risk and
in targeting organ damage observed in diabetes.
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